AstraZeneca shares fall sharply after the company reports disappointing results from a late-stage heart disease trial for its Wainua treatment. The Financial Times and Reuters report the drug does not meet its primary goal of reducing cardiovascular deaths, a key outcome in the study. Multiple outlets also describe the market reaction as steep, with shares down around 9% shortly after the announcement, and note that the decline drags on sentiment around the UK stock market. The Times similarly links the share drop to the trial miss, while other coverage emphasizes the rarity of such a setback for a large pharmaceutical company. The reporting consistently centers on the trial’s failure to achieve the targeted reduction in cardiovascular mortality, rather than on other endpoints or subgroup results. Overall, the articles portray the announcement as a negative update for AstraZeneca’s pipeline and as a significant, near-term financial and investor signal, pending further details from the company.